Rani Therapeutics Holdings, Inc. (RANI) company profile
Close on Nov 17, 2026Market cap $77.98MP/E –Yield –
About Rani Therapeutics
Pharmaceutical Preparations, SIC 2834
Rani Therapeutics is a clinical-stage biotherapeutics enterprise that develops oral delivery technologies for biologics and drugs, designed to replace traditional subcutaneous and intravenous injections. The company focuses on its proprietary, drug-agnostic RaniPill platform, which includes the RaniPill GO microtablet system and the RaniPill HC high-capacity liquid formulation capsule. Its therapeutic pipeline spans multiple indications, including obesity, inflammatory disorders, and rare diseases, featuring active candidates such as RT-114, RT-116, RT-111, and RT-117. Intended customers and commercial targets comprise partner biopharmaceutical firms seeking oral delivery mechanisms for proprietary compounds, alongside eventual end-users including patients, prescribing clinicians, and healthcare networks.
The business conducts preclinical evaluation and automated pilot manufacturing in-house while engaging external engineering contractors and global component suppliers. Clinical development activities and trial cohorts have operated across locations including Australia, with planned future commercialization spanning the United States, Europe, and Asia. Corporate headquarters and physical facility locations are not detailed in the provided excerpt, nor are formal founding dates or web domains specified.
Summary of the business section of Rani Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Rani Therapeutics Holdings, Inc.
- Headquarters
- San Jose, CA
- Address
- 2051 Ringwood Avenue 95131
- Phone
- (408) 457-3700
- Website
- ranitherapeutics.com
- Employees
- 69, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, San Francisco, California
Stock & identifiers
- Ticker
- RANI
- Exchange
- Nasdaq
- IPO date
- Aug 2, 2021
- Shares outstanding
- 139M, Jul 31, 2026
- Public float
- $65.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1856725
- CUSIP
- 753018100
- ISIN
- US7530181004
- FIGI
- BBG011R6PZ44
- Share class FIGI
- BBG011R6PZZ0
- EIN
- 86-3114789
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Talat Imran | Chief Executive Officer, Director | 474,151 |
| Alireza Javadi | Chief Technical Officer | 9,071 |
| Nicholas Maestas | Chief Financial Officer | – |
| Kate McKinley | Chief Business Officer | 17,960 |
| Svai S. Sanford | Chief Financial Officer | 258,597 |
| Mir Hashim | Chief Scientific Officer | 445,250 |
| Michelle Gilson | Director | – |
| Mir A. Imran | Director | 24,853,526 |
| Vasudev Jaiprakash Bailey | Director | – |
| Dennis A. Ausiello | Director | – |
| Jean Luc Butel | Director | 50,500 |
| Abraham Bassan | Director | – |
| Lisa Ann Rometty | Director | – |
| Maulik Nanavaty | Director | 64,345 |
| Andrew Farquharson | Director | 509,318 |
| Laureen Debuono | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Talat Imran Chief Executive Officer | $198.33K | – | $502.18K | $351.60K | $1.05M | -65% |
| Svai Sanford Chief Financial Officer | $392.71K | $139.00K | $154.99K | $259.70K | $946.40K | -27% |
| Kate McKinley Chief Business Officer | $370.47K | $130.00K | $201.57K | $241.90K | $943.94K | -25% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 2, 2021
- Offer price
- $11.00
- Securities offered
- 6,666,667
- Gross proceeds
- $73.33M
- Exchange
- Nasdaq
- First trading day
- Jul 30, 2021
- First-day close
- $11.000.0%
- Lock-up ends (est.)
- Jan 26, 2022
“ntinuing LLC Owners, through their ownership of Class B common stock, collectively will hold no economic interest in Rani Holdings and the remaining 94.0% of the voting power in Rani Holdings, at the initial public offering price of $11.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 69 full-time employees and two part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 12, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 15, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 26, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 6, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 9, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 11, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 16, 2021 | Late filing | Notification of late filing |
| Aug 2, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 26, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?